ARTICLE SUMMARY:
Biotheranostics is developing molecular tests that help guide physicians towards the right treatment regimen for their cancer patients, notably predicting the risk of late recurrence and endocrine response in early stage breast cancer patients and providing the molecular classification of metastatic cancers of unknown origin.
Many companies provide tests that enhance precision medicine in oncology, but Biotheranostics has a validated technology with high clinical utility, which improves upon current technologies and addresses gaps unfilled by other molecular tests.
